GVHD: better safe than sorry

In this issue of Blood, Takahashi et al(1) show that higher abatacept exposure decreases the occurrence of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors (URDs), without increasing the risk of relapse.

Automated summary

This study demonstrates that higher exposure to abatacept can reduce the occurrence of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors (URDs), without increasing the risk of relapse.